Nicoletta Colombo, Martin Gore

Slides:

Advertisements

Similar presentations

台北榮民總醫院婦產部主治醫師吳華席. Introduction Ovarian cancer –The lethal gynecologic cancer The major prognostic factors –Residual tumor at primary surgery –Sensitivity.

Advertisements

CALYPSO Trial: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum- Sensitive Ovarian Cancer Pujade-Lauraine.

Relapsed/Refractory Ovarian Cancer: Decision Points in Diagnosis and New Treatment Strategies Friday, March 24, 2006 Palm Springs Convention Center Primrose.

Results Increased median PFS 2.8 months No apparent increased survival. HR=0.985 CR+PR=46% Gemzar vs 36% control Independently Assessed Increased toxicity,

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature María Teresa Martínez, José Alejandro Pérez-Fidalgo, Paloma Martín-Martorell,

Metastatic melanoma treatment: Combining old and new therapies Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden Critical Reviews in Oncology /

Eribulin—A review of preclinical and clinical studies

Gastric cancer Critical Reviews in Oncology / Hematology

Umesh K. Narta, Shamsher S. Kanwar, Wamik Azmi

Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review Cloé Brami, Ting Bao, Gary Deng Critical.

Novel targets in gastric and esophageal cancer

Critical Reviews in Oncology / Hematology

© The Author(s) Published by Science and Education Publishing.

Volume 144, Issue 1, Pages (January 2017)

Philipp Dahm, Ari D. Silverstein, Alon Z

Organization of the clinical activity of Geriatric Oncology: Report of a SIOG (International Society of Geriatric Oncology) task force Silvio Monfardini,

Close or Positive Margins After Mastectomy for DCIS: Pattern of Relapse and Potential Indications for Radiotherapy Afshin Rashtian, M.D., Shawn Iganej,

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,

Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis

The case for wider use of recombinant factor VIII concentrates

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer Sandro Pignata, Enrico.

Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature Omar Abdel-Rahman,

Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey Lazzaro Repetto Critical.

Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review.

Amy M. Lin, Charles J. Ryan, Eric J. Small

Genistein: Its role in metabolic diseases and cancer

Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review.

The dose–response of salvage radiotherapy following radical prostatectomy: A systematic review and meta-analysis Christopher R. King Radiotherapy and.

A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC) Giorgio Arcangeli,

Volume 64, Pages e1-e3 (January 2017)

Abhimanyu Ghose, Ria Kundu, Tahir Latif

Critical Reviews in Oncology / Hematology

P. Therasse, S. Carbonnelle, J. Bogaerts

The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis K.

Olfa Baroudi, Amel Benammar-elgaaied

Clinically useful prognostic factors in acute myeloid leukemia

Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric.

Fig. 1 Kaplan–Meier curves of post-progression survival (PPS) in the docetaxel and best supportive care (BSC) groups. Median PPS was 5.4 months in the.

Gwo Yaw Ho, Natasha Woodward, Jermaine I.G. Coward

Critical Reviews in Oncology / Hematology

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario Alfredo Addeo, Fabrizio Tabbò, Tim Robinson, Lucio Buffoni, Silvia Novello Critical.

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer Miguel.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Survival outcomes and interval between lymphoscintigraphy and SLNB in cutaneous melanoma- findings of a large prospective cohort study Fionnuala M. O'Leary,

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Volume 148, Issue 1, Pages (January 2018)

Are patients willing to travel for better ovarian cancer care?

Hepatic resection of non-colorectal and non-neuroendocrine liver metastases – Survival benefit for patients with non-gastrointestinal primary cancers.

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

Volume 150, Issue 3, Pages (September 2018)

Volume 149, Issue 2, Pages (May 2018)

Adjuvant chemotherapy for rectal cancer – Authors' reply

Antje Timmer*, Lloyd R. Sutherland*,‡, Francois Martin§

Volume 148, Issue 1, Pages (January 2018)

The development and use of vascular targeted therapy in ovarian cancer

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Volume 143, Issue 2, Pages (November 2016)

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Volume 152, Issue 1, Pages (January 2019)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Volume 142, Issue 2, Pages (August 2016)

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer Philip E. Lammers, MD, Yu Shyr, PhD, Chung-I Li,

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

Volume 130, Issue 1, Pages (July 2013)

Skin cancer epidemic in a wireless world

Volume 151, Issue 1, Pages (October 2018)

Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy Sophie Papa, MRCP, PhD, Sanjay Popat, FRCP,

Volume 124, Issue 1, Pages (January 2012)

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Presentation transcript:

Treatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapy Nicoletta Colombo, Martin Gore Critical Reviews in Oncology / Hematology Volume 64, Issue 2, Pages 129-138 (November 2007) DOI: 10.1016/j.critrevonc.2007.04.004 Copyright © 2007 Elsevier Ireland Ltd Terms and Conditions

Fig. 1 Kaplan–Meier survival curves for (a) patients with a platinum-free interval >6 months and (b) for patients with a platinum-free interval of 6–12 months (partially platinum-sensitive disease) treated with pegylated liposomal doxorubicin (PLD) vs. topotecan demonstrate that the survival benefit was more prominent in partially platinum-sensitive patients treated with PLD. (a) HR=1.43 (95% CI: 1.01, 1.92) in 219 patients (with permission from Ref. [17]). (b) HR=1.58 (95% CI: 1.07, 2.34) in 122 patients (Personal communication, Alan N. Gordon, Dallas, Texas). Critical Reviews in Oncology / Hematology 2007 64, 129-138DOI: (10.1016/j.critrevonc.2007.04.004) Copyright © 2007 Elsevier Ireland Ltd Terms and Conditions

Fig. 2 Schema for the Gynecologic Cancer Intergroup phase III CALYPSO study. Critical Reviews in Oncology / Hematology 2007 64, 129-138DOI: (10.1016/j.critrevonc.2007.04.004) Copyright © 2007 Elsevier Ireland Ltd Terms and Conditions

Fig. 3 Schema for the phase III Gynecologic Oncology Group (GOG) 213 study evaluating combination vs. sequential chemotherapy for the treatment of platinum-sensitive ROC. Critical Reviews in Oncology / Hematology 2007 64, 129-138DOI: (10.1016/j.critrevonc.2007.04.004) Copyright © 2007 Elsevier Ireland Ltd Terms and Conditions